JPRN-UMIN000002922已完成未知
Phase I study of weekly bortezomib for patients with recurrent or refractory multiple myeloma - Phase I study of weekly bortezomib for multiple myeloma
PO IB-HOPE0 个研究点目标入组 12 人开始时间: 2009年12月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) CNS involvement 2) History of severe drug allergy 3) Active infectious diseases 4) HBs antigen or HCV antibody or HIV antibody positive 5) Significant complications which include cardiac dysfunction, liver cirrhosis, uncontrolled diabetes, renal failure 6) Interstitial pneumonitis 7) History of other active malignancy 8) Severe mental disorder
研究者
相似试验
已完成
不适用
Phase II study of bortezomib maintenance therapy for multiple myeloma patientsMultiple MyelomaJPRN-UMIN000013912ational Hospital Organization Disaster Medical Center of Japan96
进行中（未招募）
1 期
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma.Multiple MyelomaEUCTR2009-017903-28-SKHOVON Foundation1,500
进行中（未招募）
不适用
A randomized phase III study to compare Bortezomib, Melphalan,Prednisone (VMP) with High Dose Melphalan followed by Bortezomib,Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomidemaintenance in patients with newly diagnosed multiple myelomaMultiple MyelomaEUCTR2009-017903-28-LUHOVON Foundation1,500
进行中（未招募）
1 期
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2009-017903-28-ATHOVON Foundation1,500
进行中（未招募）
不适用
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myelomaMedDRA version: 16.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2009-017903-28-PTHOVON Foundation1,500